<DOC>
	<DOCNO>NCT01920555</DOCNO>
	<brief_summary>This study look efficacy , durability , safety , tolerability multiple single dos Ketamine vs. active placebo treat patient treatment resistant depression take antidepressant working .</brief_summary>
	<brief_title>Double-Blind , Placebo-Controlled Trial Ketamine Therapy Treatment-Resistant Depression ( TRD )</brief_title>
	<detailed_description>The primary objective investigate whether dos ( 0.1 mg/kg , 0.2 mg/kg , 0.5 mg/kg , 1.0 mg/kg ) ketamine superior active placebo ( midazolam 0.045 mg/kg ) therapy acute treatment patient treatment resistant depression within 72 hour ( Day 3 ) , add ongoing stable antidepressant therapy .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Male female , 1870 year old . Able read , understand , provide write , date informed consent prior screen . Diagnosed Major Depressive Disorder ( MDD ) , single recurrent , currently experience Major Depressive Episode ( MDE ) least eight week duration , prior screen . Has history TRD current MDE . Meet threshold total MADRS score great equal 20 screen baseline visit ( Day 7/28 Day 0 ) , confirm remote centralize MGH CTNI rater screen visit baseline visit . In good general health For female participant , status nonchildbearing potential use acceptable form birth control Body mass index 1835 kg/m2 Concurrent psychotherapy allow type frequency therapy stable least three month prior screen expect remain stable participation study Concurrent hypnotic therapy allow therapy stable least 4 week prior screen expect remain stable course subject 's participation study . Female childbearing potential willing use one specify form birth control study Female pregnant breastfeed Female positive pregnancy test screen baseline History current MDE failure achieve satisfactory response &gt; 7 treatment course therapeutic dose antidepressant therapy least 8 week duration current episode Total MADRS score &lt; 20 screen baseline visit , assessed remote , independent MGH CTNI rater report site Current diagnosis Substance Use Disorder ( Abuse Dependence ) exception nicotine dependence , screen within 6 month prior screen Current Axis I disorder principal focus treatment MDD secondary focus treatment past 6 month History bipolar disorder , schizophrenia schizoaffective disorder , history psychotic symptom current previous depressive episode History eat disorder within five year screen Any Axis I Axis II Disorder , screen clinically predominant MDD predominant time within 6 month prior screen Subject consider significant risk suicidal behavior course participation study Has fail respond electroconvulsive therapy ( ECT ) current depressive episode Has receive vagus nerve stimulation ( VNS ) time prior screening Has dementia , delirium , amnestic , cognitive disorder Has clinically significant abnormality screen physical examination Participation clinical trial investigational drug device within past month concurrent study participation Current episode : 1 . Hypertension , Stage 1 define systolic blood pressure ≥140mmHg diastolic blood pressure ≥90 mmHg screen two three measurement ( stand supine ) least 15 minute apart . 2 . Hypertension , Stage 1 define systolic blood pressure ≥155 mmHg diastolic blood pressure ≥99 mmHg Baseline Visit ( Visit 1 ) within 1.5 hour prior randomization two three measurement ( stand supine ) least 15 minute apart . 3 . Recent myocardial infarction ( within one year ) history myocardial infarction . 4 . Syncopal event within past year . 5 . Congestive heart failure ( CHF ) New York Heart Association Criteria &gt; Stage 2 6 . Angina pectoris . 7 . Heart rate &lt; 50 &gt; 105 beat per minute screen randomization ( Baseline Visit ) . 8 . QTcF ( Fridericiacorrected ) ≥450 msec screen randomization ( Baseline Visit ) . Current history hypertension , antihypertensives purpose lower blood pressure , either increase antihypertensive dose increase number antihypertensive drug use treat hypertension last 2 month . Chronic lung disease exclude asthma . Lifetime history surgical procedure involve brain meninges , encephalitis , meningitis , degenerative central nervous system disorder , epilepsy , mental retardation , disease/procedure/accident/intervention associate significant injury malfunction central nervous system , history significant head trauma within past 2 year Presents follow lab abnormality : 1 . Thyroid stimulate hormone outside normal limit clinically significant determine investigator . Free thyroxine ( T4 ) level may measure TSH level high . Subject exclude T4 level clinically significant . 2 . Patients diabetes mellitus fulfil follow criterion : i. Unstable diabetes mellitus define glycosylated hemoglobin ( HbA1c ) &gt; 8.5 % screen ii . Admitted hospital treatment diabetes mellitus diabetes mellitus related illness past 12 week iii . Not physician care diabetes mellitus iv . Has dose oral hypoglycaemic drug ( ) and/or diet 4 week prior screen . For thiazolidinediones ( glitazones ) period le 8 week . c. Any clinically significant abnormal laboratory result ( determine evaluation study investigator MGH CTNI medical monitor ) time screen exam . History hypothyroidism stable dosage thyroid replacement medication le 2 month prior screen . ( Subjects stable dosage thyroid replacement medication least 2 month prior screen eligible enrollment . ) History hyperthyroidism treat ( medically surgically ) less six month prior screen Any current past history physical condition investigator 's opinion might put subject risk interfere study result interpretation History positive screening urine test drug abuse screen Patients exclusionary laboratory value , require treatment exclusionary concomitant medication Patients exclusionary concomitant psychotropic medication , halflife would allow sufficient time patient free medication posttaper five halflives within maximum screening period ( 28 day ) . Patient participate study ketamine AZD6765 NMDA receptor antagonists depression receive active treatment . Patients narrow angle glaucoma Patients lifetime history PCP/Ketamine drug use Liver Function Tests high 2.5 time upper limit normal</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Depression</keyword>
	<keyword>Treatment Resistant Depression</keyword>
	<keyword>Ketamine</keyword>
	<keyword>Antidepressant</keyword>
	<keyword>MDD</keyword>
	<keyword>Major Depression</keyword>
</DOC>